首页 > 最新文献

Drug and Therapeutics Bulletin最新文献

英文 中文
Prescription charge acceptability. 处方费用可接受性。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2025-09-22 DOI: 10.1136/dtb.2025.000036
{"title":"Prescription charge acceptability.","authors":"","doi":"10.1136/dtb.2025.000036","DOIUrl":"https://doi.org/10.1136/dtb.2025.000036","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145124554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intervention to reduce sedative use. 干预以减少镇静剂的使用。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2025-09-19 DOI: 10.1136/dtb.2025.000045
{"title":"Intervention to reduce sedative use.","authors":"","doi":"10.1136/dtb.2025.000045","DOIUrl":"https://doi.org/10.1136/dtb.2025.000045","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effective medication reviews and deprescribing in primary care. 初级保健中有效的药物评价和处方。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2025-09-04 DOI: 10.1136/dtb.2025.000024

Overview of: Radcliffe E, Servin R, Cox N, et al What makes a multidisciplinary medication review and deprescribing intervention for older people work well in primary care? A realist review and synthesis. BMC Geriatr 2023;23:591.

概述：Radcliffe E， Servin R， Cox N等。是什么使得多学科的药物回顾和老年人的处方干预在初级保健中效果良好？现实主义的回顾与综合。中国生物医学工程学报，2009;23:591。
{"title":"Effective medication reviews and deprescribing in primary care.","authors":"","doi":"10.1136/dtb.2025.000024","DOIUrl":"10.1136/dtb.2025.000024","url":null,"abstract":"<p><p><b>Overview of:</b> Radcliffe E, Servin R, Cox N, <i>et al</i> What makes a multidisciplinary medication review and deprescribing intervention for older people work well in primary care? A realist review and synthesis. <i>BMC Geriatr</i> 2023;23:591.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"131"},"PeriodicalIF":0.0,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
(I)mproving antibiotic susceptibility reports. （一）完善抗生素敏感性报告。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2025-09-04 DOI: 10.1136/dtb.2025.000025
Syba Sunny
{"title":"(I)mproving antibiotic susceptibility reports.","authors":"Syba Sunny","doi":"10.1136/dtb.2025.000025","DOIUrl":"https://doi.org/10.1136/dtb.2025.000025","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"63 9","pages":"130"},"PeriodicalIF":0.0,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144999961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medication-overuse headache overlapping with serotonin syndrome. 药物滥用性头痛与血清素综合征重叠。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2025-09-04 DOI: 10.1136/dtb.2024.256464rep
Sanjay Prakash, Harsh Patel, Chetsi Sudhir Shah
{"title":"Medication-overuse headache overlapping with serotonin syndrome.","authors":"Sanjay Prakash, Harsh Patel, Chetsi Sudhir Shah","doi":"10.1136/dtb.2024.256464rep","DOIUrl":"10.1136/dtb.2024.256464rep","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"139-143"},"PeriodicalIF":0.0,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug treatment of chronic heart failure with reduced ejection fraction. 慢性心力衰竭伴射血分数降低的药物治疗。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2025-09-04 DOI: 10.1136/dtb.2024.000050
Aamir Shamsi, Daniel Sado

Heart failure (HF) is a progressive clinical syndrome characterised by insufficient cardiac output due to structural and functional abnormalities of the heart, which can then lead to breathlessness, fatigue and fluid overload. HF has an associated high morbidity and mortality rate as well as a significant impact on healthcare resources; for example, in the UK, it accounts for 5% of National Health Service (NHS) emergency admissions. This review focuses on pharmacological treatment of chronic HF with reduced ejection fraction (HFrEF), which affects approximately 60% of patients with HF. Patient outcomes are determined by early diagnosis and individualised treatment. The cornerstone of HFrEF management consists of four key medication classes: ACE inhibitors or angiotensin receptor-neprilysin inhibitor (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRA) and sodium-glucose co-transporter 2 inhibitors (SGLT2i). These medications constitute the four pillars of HfrEF treatment. Each class has a distinct mechanism that when used together synergistically enhances patient outcomes. In this review we discuss drug treatment options and key considerations in the management of people with chronic HFrEF. The review also highlights the importance of medication management, addressing complications and promoting lifestyle modifications.

心力衰竭（HF）是一种进行性临床综合征，其特征是由于心脏结构和功能异常导致心输出量不足，从而导致呼吸困难、疲劳和液体过载。心衰具有相关的高发病率和死亡率以及对医疗资源的重大影响；例如，在英国，它占国民健康服务（NHS）紧急入院人数的5%。这篇综述的重点是慢性心衰伴射血分数降低（HFrEF）的药物治疗，这影响了大约60%的心衰患者。患者的预后取决于早期诊断和个体化治疗。HFrEF治疗的基础包括四类关键药物：ACE抑制剂或血管紧张素受体-neprilysin抑制剂（ARNI）、β受体阻滞剂、矿皮质激素受体拮抗剂（MRA）和钠-葡萄糖共转运蛋白2抑制剂（SGLT2i）。这些药物构成了HfrEF治疗的四大支柱。每一类药物都有不同的机制，当它们一起协同使用时，可以提高患者的预后。在这篇综述中，我们讨论了慢性HFrEF患者的药物治疗选择和关键注意事项。该综述还强调了药物管理、解决并发症和促进生活方式改变的重要性。
{"title":"Drug treatment of chronic heart failure with reduced ejection fraction.","authors":"Aamir Shamsi, Daniel Sado","doi":"10.1136/dtb.2024.000050","DOIUrl":"https://doi.org/10.1136/dtb.2024.000050","url":null,"abstract":"<p><p>Heart failure (HF) is a progressive clinical syndrome characterised by insufficient cardiac output due to structural and functional abnormalities of the heart, which can then lead to breathlessness, fatigue and fluid overload. HF has an associated high morbidity and mortality rate as well as a significant impact on healthcare resources; for example, in the UK, it accounts for 5% of National Health Service (NHS) emergency admissions. This review focuses on pharmacological treatment of chronic HF with reduced ejection fraction (HFrEF), which affects approximately 60% of patients with HF. Patient outcomes are determined by early diagnosis and individualised treatment. The cornerstone of HFrEF management consists of four key medication classes: ACE inhibitors or angiotensin receptor-neprilysin inhibitor (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRA) and sodium-glucose co-transporter 2 inhibitors (SGLT2i). These medications constitute the four pillars of HfrEF treatment. Each class has a distinct mechanism that when used together synergistically enhances patient outcomes. In this review we discuss drug treatment options and key considerations in the management of people with chronic HFrEF. The review also highlights the importance of medication management, addressing complications and promoting lifestyle modifications.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"63 9","pages":"133-138"},"PeriodicalIF":0.0,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144999977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term outcomes for cancer drugs with accelerated approval. 加速审批的抗癌药物的长期疗效。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2025-09-04 DOI: 10.1136/dtb.2025.000016

Overview of: Liu ITT, Kesselheim AS, Cliff ERS. Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval. JAMA 2024;331:1471-9.

综述：Liu ITT， Kesselheim AS, Cliff ERS。加速批准抗癌药物的临床获益和监管结果《美国医学会杂志》2024;331:1471-9。
{"title":"Long-term outcomes for cancer drugs with accelerated approval.","authors":"","doi":"10.1136/dtb.2025.000016","DOIUrl":"10.1136/dtb.2025.000016","url":null,"abstract":"<p><p><b>Overview of:</b> Liu ITT, Kesselheim AS, Cliff ERS. Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval. <i>JAMA</i> 2024;331:1471-9.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"132"},"PeriodicalIF":0.0,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can we improve information accompanying drug safety warnings? 我们能否改进伴随药物安全警告的信息？
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2025-07-31 DOI: 10.1136/dtb.2024.000051
Julian Treadwell
{"title":"Can we improve information accompanying drug safety warnings?","authors":"Julian Treadwell","doi":"10.1136/dtb.2024.000051","DOIUrl":"10.1136/dtb.2024.000051","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"115-116"},"PeriodicalIF":0.0,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tirzepatide for weight reduction in people without diabetes. 替西帕肽用于非糖尿病患者减肥。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2025-07-31 DOI: 10.1136/dtb.2025.000018

Overview of: Jastreboff AM, Aronne LJ, Ahmad NN, et al Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205-216.

Jastreboff AM, Aronne LJ, Ahmad NN，等。替西帕肽治疗肥胖症的研究综述。中华医学杂志（英文版）；2009;37(1):391 - 391。
{"title":"Tirzepatide for weight reduction in people without diabetes.","authors":"","doi":"10.1136/dtb.2025.000018","DOIUrl":"10.1136/dtb.2025.000018","url":null,"abstract":"<p><p><b>Overview of:</b> Jastreboff AM, Aronne LJ, Ahmad NN, <i>et al</i> Tirzepatide Once Weekly for the Treatment of Obesity. <i>N Engl J Med</i> 2022;387:205-216.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"117"},"PeriodicalIF":0.0,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AI and DTB: the computer says no. AI和DTB：计算机说不。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2025-07-31 DOI: 10.1136/dtb.2025.000030
David Phizackerley
{"title":"AI and DTB: the computer says no.","authors":"David Phizackerley","doi":"10.1136/dtb.2025.000030","DOIUrl":"10.1136/dtb.2025.000030","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"114"},"PeriodicalIF":0.0,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Drug and Therapeutics Bulletin
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1